Serum resistin: Physiology, pathophysiology and implications for heart failure

Biomarkers in Medicine

Volumn 4, Issue 3, 2010, Pages 445-452

  Bhalla, Vikas ^a   Kalogeropoulos, Andreas ^a   Georgiopoulou, Vasiliki ^a   Butler, Javed ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Biomarker; Heart failure; Insulin resistance; Resistin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROGENESIS; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIET; DRUG EFFECT; EXERCISE; GLUCOSE METABOLISM; HEART DEATH; HEART FAILURE; HEART MUSCLE CELL; HOSPITAL READMISSION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; KAPLAN MEIER METHOD; LABORATORY TEST; METABOLIC SYNDROME X; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; REVIEW; SERUM; SURVIVAL RATE; UNSTABLE ANGINA PECTORIS;

HEART FAILURE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; RESISTIN; RISK FACTORS;

ANIMALIA;

EID: 77953729528     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.17     Document Type: Review

References (54)

1. Rosamond W, Flegal K, Friday G et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115(5), e69-e171 (2007).
2. Haldeman GA, Croft JB, Giles WH, Rashidee A: Hospitalization of patients with heart failure: national hospital discharge survey, 1985 to 1995. Am. Heart J. 137(2), 352-360 (1999).
3. Roger VL, Weston SA, Redfield MM et al.: Trends in heart failure incidence and survival in a community-based population. JAMA 292(3), 344-350 (2004).
4. Jung HS, Park KH, Cho YM et al.: Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc. Res. 69(1), 76-85 (2006).
5. Curat CA, Wegner V, Sengenès C et al.: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49(4), 744-747 (2006).
6. Frankel DS, Vasan RS, D'Agostino RB Sr et al.: Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J. Am. Coll. Cardiol. 53(9), 754-762 (2009).
7. Steppan CM, Bailey ST, Bhat S et al.: The hormone resistin links obesity to diabetes. Nature 409(6818), 307-312 (2001).
8. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111(7), 932-939 (2005).
9. Kim M, Oh JK, Sakata S et al.: Role of resistin in cardiac contractility and hypertrophy. J. Mol. Cell. Cardiol. 45(2), 270-280 (2008).
10. Kim M, Oh JK, Sakata S et al.: An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 1(2), e45 (2004).
11. Weikert C, Westphal S, Berger K et al.: Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J. Clin. Endocrinol. Metab. 93(7), 2647-2653 (2008).
12. Ellington AA, Malik AR, Klee GG et al.: Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 50(4), 708-714 (2007).
13. Efstathiou SP, Tsiakou AG, Tsioulos DI et al.: Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin. Chim. Acta 378(1-2), 78-85 (2007).
14. Takeishi Y, Niizeki T, Arimoto T et al.: Serum resistin is associated with high risk in patients with congestive heart failure - a novel link between metabolic signals and heart failure. Circ. J. 71(4), 460-464 (2007).
15. Butler J, Kalogeropoulos A, Georgiopoulou V et al.: Serum resistin concentrations and risk of new onset heart failure in older persons. The Health, Aging, and Body Composition (Health ABC) Study. Arterioscler. Thromb. Vasc. Biol. 29(7), 1144-1149 (2009).
16. Rajala MW, Obici S, Scherer PE, Rossetti L: Adipose-derived resistin and gut-derived resistin-like molecule-b selectively impair insulin action on glucose production. J. Clin. Invest. 111(2), 225-230 (2003).
17. Moon B, Kwan JJ, Duddy N, Sweeney G, Begum N: Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am. J. Physiol. Endocrinol. Metab. 285(1), E106-E115 (2003).
18. Graveleau C, Zaha VG, Mohajer A et al.: Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J. Biol. Chem. 280(36), 31679-31685 (2005).
19. Kadoglou NP, Iliadis F, Liapis CD, Perrea D, Angelopoulou N, Alevizos M: Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with Type 2 diabetes. Diabetes Care 30(9), 2242-2244 (2007).
20. Taegtmeyer H, McNulty P, Young ME: Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 105(14), 1727-1733 (2002). (Pubitemid 34298619)
21. Taegtmeyer H: Switching metabolic genes to build a better heart. Circulation 106(16), 2043-2045 (2002).
22. Sheng CH, Di J, Jin Y et al.: Resistin is expressed in human hepatocytes and induces insulin resistance. Endocrine 33(2), 135-143 (2008).
23. Petersen KF, Shulman GI: Etiology of insulin resistance. Am. J. Med. 119(5 Suppl. 1), S10-S16 (2006).
24. Wang BW, Hung HF, Chang H, Kuan P, Shyu KG: Mechanical stretch enhances the expression of resistin gene in cultured cardiomyocytes via tumor necrosis factor-a. Am. J. Physiol. Heart Circ. Physiol. 293(4), H2305-H2312 (2007).
25. Al Zadjali MA, Khan F, Choy A et al.: Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J. Am. Coll. Cardiol. 53(9), 747-753 (2009).
26. Nikolaidis LA, Mankad S, Sokos GG et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109, 962-965 (2004).
27. Paolisso G, Rizzo MR, Gambardella A et al.: Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Am. J. Cardiol. 83(9), 1338-1344 (1999).
28. Kunnari A, Ukkola O, Päivänsalo M, Kesäniemi YA: High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J. Clin. Endocrinol. Metab. 91(7), 2755-2760 (2006).
29. Qi Q, Wang J, Li H et al.: Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur. J. Endocrinol. 159(5), 585-593 (2008).
30. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL: Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur. J. Endocrinol. 156(2), 279-284 (2007).
31. Verma S, Li SH, Wang CH et al.: Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108(6), 736-740 (2003).
32. Burnett MS, Lee CW, Kinnaird TD et al.: The potential role of resistin in atherogenesis. Atherosclerosis 182(2), 241-248 (2005).
33. Dick GM, Katz PS, Farias M 3rd et al.: Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation. Am. J. Physiol. Heart Circ. Physiol. 291(6), H2997-H3002 (2006).
34. Esposito K, Nappo F, Marfella R et al.: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106(16), 2067-2072 (2002).
35. Rothwell SE, Richards AM, Pemberton CJ: Resistin worsens cardiac ischaemia-reperfusion injury. Biochem. Biophys. Res. Commun. 349(1), 400-407 (2006).
36. Sun M, Chen M, Dawood F et al.: Tumor necrosis factor-a mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115(11), 1398-1407 (2007).
37. Sun M, Dawood F, Wen WH et al.: Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110, 3221-3228 (2004).
38. Satoh M, Nakamura M, Saitoh H et al.: Tumor necrosis factor-a-converting enzyme and tumor necrosis factor-a in human dilated cardiomyopathy. Circulation 99, 3260-3265 (1999).
39. Kassiri Z, Oudit GY, Sanchez O et al.: Combination of tumor necrosis factor-a ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ. Res. 97, 380-390 (2005).
40. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236-241 (1990).
41. Gurevitch J, Frolkis I, Yuhas Y et al.: Tumor necrosis factor-a is released from the isolated heart undergoing ischemia and reperfusion. J. Am. Coll. Cardiol. 28, 247-252 (1996).
42. Nian M, Lee P, Khaper N, Liu P: Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 94(12), 1543-1553 (2004).
43. Witteles RM, Fowler MB: Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J. Am. Coll. Cardiol. 51(2), 93-102 (2008).
44. Kawanami D, Maemura K, Takeda N et al.: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem. Biophys. Res. Commun. 314(2), 415-419 (2004).
45. Rajala MW, Qi Y, Patel HR et al.: Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 53(7), 1671-1679 (2004).
46. Qi Y, Nie Z, Lee YS et al.: Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 55(11), 3083-3090 (2006).
47. Butler J, Kalogeropoulos A, Georgiopoulou V et al.: Incident heart failure prediction in the elderly: the Health ABC Heart Failure Score. Circ. Heart Fail. 1(2), 125-133 (2008).
48. Derosa G, Fogari E, D'Angelo A et al.: Metabolic effects of telmisartan and irbesartan in Type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J. Clin. Pharm. Ther. 32(3), 261-268 (2007). (Pubitemid 46699517)
49. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298(10), 1180-1188 (2007).
50. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP et al.: Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358(24), 2545-2559 (2008).
51. Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D: Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am. J. Kidney Dis. 42(1), 62-66 (2003).
52. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM: Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res. 10(1), 1-5 (2002).
53. Nagaev I, Smith U: Insulin resistance and Type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun. 285(2), 561-564 (2001).
54. Yaturu S, Daberry RP, Rains J, Jain S: Resistin and adiponectin levels in subjects with coronary artery disease and Type 2 diabetes. Cytokine 34(3-4), 219-223 (2006). (Pubitemid 44038577)